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Summary A 65-year-old man with advanced renal cell carcinoma was admitted
due to continuing chest pain at rest. Two weeks before his admission, sorafenib had
been started. He was diagnosed with non-ST-elevation myocardial infarction by lab-
oratory data and electrocardiogram. Enhanced heart magnetic resonance imaging
also showed subendocardial infarction. However, there was no stenosis in coronary
arteries on angiography. Coronary artery spasm was induced by a provocative test.
Cessation of sorafenib and administration of Ca-channel blocker and nitrates ame-
liorated his symptoms, but relapse occurred after resumption of sorafenib. Addition
of oral nicorandil reduced his symptoms and maintained stable angina status.
We report the ﬁrst case of sorafenib-induced coronary artery spasm. Sorafenib is
a multikinase inhibitor that targets signaling pathways necessary for cellular prolif-
eration and survival. On the other hand, the Rho/ROCK pathway has an important
role in the pathogenesis of coronary artery spasm. Our report may show an adverse
effect on the Rho/ROCK pathway by sorafenib use.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.∗ Corresponding author. Tel.: +81 96 370 3111;
fax: +81 96 370 4005.
E-mail address: junkanki@kumachu.gr.jp (S. Oshima).
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doi:10.1016/j.jjcc.2009.03.009ntroductionorafenib is a multikinase inhibitor which inhibits
variety of solid tumor growths. Some randomized
rials have shown that sorafenib therapy prolongs
rogression-free survival, especially in renal cell
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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tigure 1 Electrocardiogram on hospital admission.
arcinoma, but it also has some adverse effects,
ncluding cardiac ischemia [1]. Its mechanisms are
ot fully understood, and cardiac adverse effect is
ne of the reasons for the discontinuation of treat-
ent.
Here we present a case of myocardial infarction
hat was not caused by coronary artery sclerosis but
y coronary artery spasm, secondary to sorafenib
se.
ase report
65-year-old Japanese man with advanced renal
ell carcinoma visited our hospital due to chest
ain lasting for 3 h. Two weeks before his visit,
orafenib had been started for advanced renal
ell carcinoma. He had never experienced chest
ymptoms before sorafenib use. His only coronary
isk factor was hypertension and he had no other
isk factors including dyslipidemia, diabetes, or
moking. Hypertension had been exacerbated by
orafenib use. On admission, the electrocardio-
ram (ECG) showed ST-segment depression in II,
II, and aVF (Fig. 1). A blood test showed a white
lood cell count of 11,600mm−3, a creatine kinase
CK) of 148U/l, CK-MB 31.8U/l, and myocardial
roponin I of 2.18 ng/ml. We diagnosed acute coro-
ary syndrome and started infusion of isosorbide
initrate. After infusion, his symptoms disappeared
nd ST-segment normalized on ECG. A transtho-
acic echocardiogram showed non-obstructive
eft ventricular hypertrophy with normal left
entricle chamber size and there were no apparent
all motion abnormalities. However, CK levels
ncreased and the maximum value was observed at
0 h after the onset (maximum CK: 345U/l; CK-MB:
9U/l). We conﬁrmed non-ST-elevation myocardial
nfarction.We used infusion of isosorbide dinitrate for 3
ays and ceased sorafenib use. During this treat-
ent course, his chest pain did not reappear. On
ay 4, we performed coronary angiography. There
as no stenosis of the coronary arteries. So we
a
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erformed ergonovine provocative test. Infusion of
2g of ergonovine into the right coronary artery
rovoked chest pain which he had experienced
efore and 99% stenosis with delayed ﬂow (Fig. 2,
eft). ST-segment elevation was observed in lead
II and aVF (Fig. 2, right). We diagnosed coronary
pastic angina.
Enhanced heart magnetic resonance imaging
howed subendocardial late gadolinium enhance-
ent in the anterior wall and inferoseptal wall.
nd the T2 weighted image showed a high signal
t the anterior wall, which was considered to be
yocardial edema caused by infarction (Fig. 3).
We started administration of oral nifedipine
20mg every 12 h), ﬂuvastatin (20mg every 24 h),
alsartan (80mg every 24 h) and transdermal
itrates. His symptoms did not recur in the hos-
ital stay. At ﬁrst, we stopped sorafenib use for
he fear of exacerbating angina, but the patient
equested it, so we restarted sorafenib use and
tarted strict follow up in the outpatient clinic.
fter 1 month, his symptoms recurred once to twice
er month but were controlled by oral nitroglycerin
aken as needed. We added oral nicorandil (5mg
very 8 h), and he maintained a stable angina status
or 6 months.
iscussion
e witnessed myocardial infarction with angio-
raphically normal coronary arteries, and onset and
elapse of chest symptoms related to sorafenib
se. There were no other changes in medication
r lifestyle except for sorafenib use. This is the
rst report that implies a relationship between
orafenib use and coronary artery spasm.
Sorafenib is a multikinase inhibitor that targets
oth Raf and vascular endothelial growth factor and
latelet-derived growth factor receptor tyrosine
inase signaling [1]. One of them, Raf, activates
ts downstream effectors MEK and ERK, and these
athways regulate cellular proliferation and sur-
ival. Raf kinases are overactivated in a variety of
olid tumor cases, and sorafenib is the ﬁrst oral
nhibitor that targets Raf kinases. It inhibits tumor
rowth and some randomized trials have shown
ts efﬁcacy against advanced carcinomas [2,3]. In
dvanced clear-cell renal cell carcinoma, sorafenib
herapy prolongs progression-free survival but it
lso causes some adverse events including cardiac
schemia [2]. Its mechanisms are not fully under-
tood.
Coronary artery spasm plays an important role in
he pathogenesis of cardiac ischemia [4]. Coronary
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dFigure 2 Infusion of ergonovine into the right coronary
was no severe stenosis after nitrate infusion (left lower).
provocative test (right EM).
artery spasm has been induced, with signiﬁcant high
rates, in patients with recent myocardial infarc-
tion, especially Japanese [5,6]. It is partly because
of myocardial infarction occurring in patients with
normal coronary arteries [7]. Coronary spasm is
a hyper-contraction of coronary smooth muscle.
Enhanced Ca2+ sensitization plays a critical role in
the genesis of coronary spasm [4]. Some studies
showed activation of small GTPase RhoA and its
downstream effector, Rho-kinase (ROCK), leading
to augmentation of Ca2+ sensitization [8—10]. This
activation of the Rho/ROCK pathway was also con-
ﬁrmed in porcine models of coronary artery spasm
[11].
There is no report that shows the relation-
ship between the Raf/MEK/ERK pathway and the
d
S
s
iry provoked coronary artery spasm (left upper). There
gment elevation was observed in lead III and aVF during
ho/ROCK pathway in coronary smooth muscle.
owever, some studies showed that Raf or MEK
ediates an inactivation of the Rho/ROCK pathway
12,13]. Sorafenib use downregulates MEK activity,
o it may cause upregulation of the Rho/ROCK path-
ay and augmentation of Ca2+ sensitization leading
o the exacerbation of coronary artery spasm.
Some anticancer drugs also have a side effect of
yocardial ischemia [14]. However, the mechanism
f relation between ischemic event and drug use is
ot fully understood. One reason is these anticancer
rugs mainly act on the cell-cycle system and these
iverse effects mask the etiological mechanism.
orafenib is a more speciﬁc drug that targets kinase
ignaling, so this phenomenon implies an interest-
ngmechanism of spasm formation by sorafenib use.
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induced inhibition of the ROCK/LIMK/coﬁlin pathway. J Biol
Chem 2004;279:1885—91.igure 3 The ﬁndings of enhanced heart magnetic reson
n the anterior wall and inferoseptal wall was observed (l
all (right).
When we have drug-induced coronary artery
pasm, normally we have to cease the causative
rug, but in this case, the patient insisted on
ontinuing sorafenib. We managed to meet the
atient’s wish by adding anti-spasm therapies. Cur-
ently, sorafenib is the last hope for patients with
dvanced solid tumors. Giving sorafenib as combi-
ation therapy with anti-spasm medications, such
s calcium-channel blockers, nitrates, and statins
ay allow for its continuation even in such cases.
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